We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EMA Updates Brexit Guidance With Info for Generics Manufacturers
EMA Updates Brexit Guidance With Info for Generics Manufacturers
The European Medicines Agency and the European Commission broadened their guidance on Brexit to include new information for manufacturers of orphan drugs, generics and biosimilars, as well as hybrid medicines that rely on reference product data as well as new clinical trial findings.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor